PartitionBio is a UK-based biotech company developing next-generation drug delivery systems using biomolecular condensates formed through liquid-liquid phase separation (LLPS). Their non-viral platform enables efficient delivery of macromolecules like nucleic acids and proteins into human cells, aiming to improve therapeutic outcomes. PartitionBio is advancing accessible solutions for global health.